Repligen

Yahoo Finance • 8 hours ago

RadNet, Evolent Health, Illumina, Charles River Laboratories, and Repligen Stocks Trade Down, What You Need To Know

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as investors reacted to escalating uncertainty tied to the U.S.-Iran conflict and poli... Full story

Yahoo Finance • 15 days ago

2 Growth Stocks Set to Flourishand 1 We Turn Down

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle. The risks that can come from buying these asse... Full story

Yahoo Finance • 24 days ago

Signatera Oncology Test Drives Natera’s (NTRA) Growth

Carillon Tower Advisers, an investment management company, released its fourth-quarter 2025 investor letter for the “Carillon Eagle Mid Cap Growth Fund”. A copy of the letter can be downloaded here. The fourth quarter of 2025 saw mixed res... Full story

Yahoo Finance • 28 days ago

Privia Health, Repligen, and RadNet Shares Plummet, What You Need To Know

What Happened? A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. The Producer Price Index (PPI), a key measure of inflation at... Full story

Yahoo Finance • last month

How The Repligen (RGEN) Narrative Is Shifting With New Targets M&A Plans And Products

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. The updated fair value for Repligen is set at US$190.89, with analysts treating this as a recali... Full story

Yahoo Finance • last month

Repligen (RGEN) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Feb. 24, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer — Olivier Loeillot Chief Financial Officer — Jason Garland Vice President, Investor Relations — Jacob Jo... Full story

Yahoo Finance • last month

Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarterFull year 2025 revenue of $738 million, a year-over-year increase of 16% for both reported an... Full story

Yahoo Finance • last month

Repligen Corp. (RGEN) Rose as Industrial Destocking Decreased and Order Patterns Stabilized

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2025 investor letter. As many believe, US equities experienced solid returns in 2025, with double-digit gains across all major indices, yet underlying con... Full story

Yahoo Finance • last month

Repligen to Report Fourth Quarter and Full Year 2025 Financial Results

Repligen Corporation Webcast and Conference Call to Be Held Tuesday, February 24, 2026, at 8:30 a.m. ET WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its... Full story

Yahoo Finance • 2 months ago

Repligen is Now Oversold (RGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the R... Full story

Yahoo Finance • 3 months ago

Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference

Repligen Corporation WALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the J.P. Morgan... Full story

Yahoo Finance • 4 months ago

Repligen Corporation to Present at Evercore Healthcare Conference

WALTHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participate in the 8th Annual Evercore Healthca... Full story

Yahoo Finance • 4 months ago

Three Companies Estimated To Be Priced Below Their Intrinsic Value In November 2025

As the Dow Jones Industrial Average reaches new heights amid optimism surrounding a potential end to the U.S. government shutdown, investors are closely watching market fluctuations with mixed performances across major indices. In this env... Full story

Yahoo Finance • 5 months ago

Repligen beats top-line and bottom-line estimates; updates FY25 outlook

* Repligen press release [https://seekingalpha.com/pr/20281673-repligen-reports-third-quarter-2025-financial-results-and-updates-full-year-2025-financial] (NASDAQ:RGEN [https://seekingalpha.com/symbol/RGEN]): Q3 Non-GAAP EPS of $0.46 bea... Full story

Yahoo Finance • 5 months ago

Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Revenue of $189 million, year-over-year increase of 22% as reported and 18% organic with double-digit reported growth across all franchisesOrders increased sequentially and greater than 20% year-over-yearIncreasing revenue guidance to a ra... Full story

Yahoo Finance • 5 months ago

Can Margin Pressures at Repligen (RGEN) Reveal Deeper Shifts in Management’s Investment Strategy?

Recent news reports that Repligen's core business has been underperforming, with declining organic revenue and rising costs leading to a significant drop in adjusted operating margin. This operational underperformance has raised concerns a... Full story

Yahoo Finance • 5 months ago

Repligen to Report Third Quarter 2025 Financial Results

WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2025 financial results on Tuesday, October 28, 2025. The Company will issue a press relea... Full story

Yahoo Finance • 6 months ago

Myriad Genetics, Omnicell, Globus Medical, Repligen, and Teleflex Stocks Trade Down, What You Need To Know

What Happened? A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. The president's tone and the suggestion of canceling... Full story

Yahoo Finance • 6 months ago

These small cap stocks are poised for a comeback – Palisade Capital’s Dan Veru

[Markets Open After S&P Falls Nearly 4% On Monday] Spencer Platt/Getty Images News Dan Veru, chief investment officer and senior partner at Palisade Capital Management, believes small cap stocks (NYSEARCA:IWM [https://seekingalpha.com/sym... Full story

Yahoo Finance • 7 months ago

Repligen Corporation to Present at Upcoming September Conferences

WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending three upcoming investor conferences.... Full story